HC Wainwright Reaffirms “Buy” Rating for Compass Therapeutics (NASDAQ:CMPX)

HC Wainwright restated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPXFree Report) in a research report released on Monday morning, Benzinga reports. The brokerage currently has a $10.00 price objective on the stock.

Separately, Wedbush reissued an outperform rating and set a $8.00 price objective on shares of Compass Therapeutics in a research note on Friday, March 22nd.

Read Our Latest Stock Report on Compass Therapeutics

Compass Therapeutics Stock Performance

CMPX stock opened at $1.31 on Monday. The firm has a fifty day moving average price of $1.57 and a 200 day moving average price of $1.66. Compass Therapeutics has a fifty-two week low of $1.15 and a fifty-two week high of $3.45. The firm has a market cap of $180.24 million, a PE ratio of -3.64 and a beta of 0.89.

Compass Therapeutics (NASDAQ:CMPXGet Free Report) last issued its quarterly earnings data on Monday, May 13th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.03. On average, equities analysts predict that Compass Therapeutics will post -0.39 EPS for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Several institutional investors have recently made changes to their positions in CMPX. Opaleye Management Inc. purchased a new position in Compass Therapeutics during the 1st quarter valued at $6,277,000. Element Capital Management LLC purchased a new stake in shares of Compass Therapeutics during the fourth quarter valued at $458,000. Pennant Investors LP bought a new position in shares of Compass Therapeutics in the fourth quarter worth about $310,000. Blackstone Inc. increased its stake in Compass Therapeutics by 3.1% in the 3rd quarter. Blackstone Inc. now owns 6,189,551 shares of the company’s stock worth $12,193,000 after buying an additional 188,811 shares during the period. Finally, CM Management LLC lifted its holdings in Compass Therapeutics by 148.0% during the 1st quarter. CM Management LLC now owns 310,000 shares of the company’s stock valued at $614,000 after buying an additional 185,000 shares in the last quarter. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

(Get Free Report)

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

See Also

Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.